Instrument NamePfizer IncInstrument Symbol(PFE-N)

Instrument ExchangeNYSE

Selling cash secured puts on stocks an investor is happy to take ownership of is a great way to generate some extra income.

/CNW/ - Today, Pfizer Canada announced that Health Canada has granted a Notice of Compliance (NOC) for LITFULO™ (ritlecitinib). A once-daily oral treatment,...

Pfizer shares have fallen by double digits this year.

For growth investors, it may be time to sell this pharma stock for tax-loss harvesting purposes.

This company famously helps manage a prevalent chronic illness.

These stocks have room to run -- next year and over the long term.

Stocks gained ground on Wall Street as the market comes off its best month in more than a year

Stocks that traded heavily or had substantial price changes on Friday: Dell, Marvell Technology fall; Ulta Beauty, UiPath rise

The big drugmaker delivered bad news for its top pipeline program.

Pfizer shares sank Friday when the drugmaker announced that it was abandoning a twice-daily obesity treatment after more than half the patients in a clinical trial stopped taking it

A survey of North American equities heading in both directions

While Pfizer will now focus on a once-daily version, the decision still marks a blow to its ambitions to become an early contender in a booming market for weight-loss drugs

With seemingly back in bullish mode, it’s a good time to run the Bull Call Spread Screener.

Small and large dividend stock and ETF investors can use covered calls and puts trades to generate monthly income from options premiums and options trading.

Small and large dividend stock and ETF investors can use covered calls and puts trades to generate monthly income from options premiums and options trading.

An upcoming mid-stage readout may not spark a trend reversal in the big pharma's shares.

Looking for analysts' favorite stock picks in a traditionally defensive sector, with solid dividend payments to help boost your returns? Here's a look at three stocks for income investors to consider at current levels.

The company keeps falling out of favor with the market.

Ginkgo Bioworks has been securing deals with many top companies, but will they pay off for the business?

These companies are leaders in their industries.

Nobody is sure about the market's direction today; these are the stocks that can offer you a good chunk of growth at very little downside risk

Investors have favored an exciting billion-dollar opportunity at Eli Lilly.

As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results

It has plenty of money, but it'll be facing plenty of competition, too.